Atul Suri, MD
Nephrology · Greenbelt, MDNPI 1326042144
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $23,625 of the $30,339 with a category attached, or 77.9%. AstraZeneca accounts for 80.4% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2020 at $14,936 and has fallen 93.9% since, to $910 in 2025. Among nephrology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 314 payments — averaging $96.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$24K
- Vifor Pharma, Inc.$801
- Amgen$712
- Otsuka America Pharmaceutical, Inc.$576
- Fresenius USA Marketing, Inc.$393
- OPKO Pharmaceuticals, LLC$351
- plus $3K from 24 others
Across 27 payments — averaging $3977.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$72K
- Merck$33K
- Novo Nordisk AS$2K
What the payments were for
- Consulting fees$23,62578%
- Food & beverage$6,13620%
- Education$5782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $24,407 |
| Vifor Pharma, Inc. | 40 | $801 |
| Amgen(2 entities) | 37 | $712 |
| Otsuka America Pharmaceutical, Inc. | 29 | $576 |
| Fresenius USA Marketing, Inc. | 20 | $393 |
| OPKO Pharmaceuticals, LLC | 16 | $351 |
| Akebia Therapeutics Inc | 15 | $324 |
| Bayer | 16 | $324 |
| Mallinckrodt Hospital Products Inc. | 8 | $283 |
| Novartis | 12 | $266 |
| Aurinia Pharma U.S., Inc. | 10 | $222 |
| Bard Peripheral Vascular, Inc. | 1 | $203 |
| GSK | 8 | $198 |
| Travere Therapeutics, Inc. | 10 | $186 |
| Mallinckrodt Enterprises LLC | 5 | $186 |
| Ardelyx, Inc. | 6 | $121 |
| ANI Pharmaceuticals, Inc. | 5 | $113 |
| Calliditas Therapeutics US Inc. | 6 | $112 |
| Genentech USA, Inc. | 3 | $104 |
| Lilly USA, LLC | 4 | $85 |
| Boehringer Ingelheim | 4 | $74 |
| Philips North America LLC | 1 | $67 |
| Scpharmaceuticals Inc. | 2 | $60 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $56 |
| Novo Nordisk | 1 | $25 |
| Sanofi | 1 | $23 |
| Kyowa Kirin, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Baxter Healthcare | 1 | $16 |
| Johnson & Johnson | 1 | $13 |
How this compares
$30,339 in reported general payments places this provider in the 95th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JynarqueTolvaptan | 12 | $237,242 |
| VelphoroSucroferric Oxyhydroxide | 38 | $90,590 |
| VeltassaPatiromer Calcium Sorbitex | 34 | $52,588 |
| Sevelamer Carbonate | 98 | $37,596 |
| FarxigaDapagliflozin Propanediol | 22 | $24,763 |
| KerendiaFinerenone | 30 | $23,943 |
| Cinacalcet Hcl | 23 | $5,818 |
| Calcium Acetate | 19 | $1,555 |
| Calcitriol | 82 | $1,336 |
| Amlodipine Besylate | 173 | $1,060 |
| Gentamicin Sulfate | 20 | $933 |
| Bumetanide | 16 | $878 |
| Losartan Potassium | 85 | $813 |
| Doxazosin Mesylate | 20 | $648 |
| Carvedilol | 59 | $578 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Jynarque | $576 | $237,24212 claims |
| Fresenius USA Marketing, Inc.Velphoro | $393 | $90,59038 claims |
| AstraZenecaFarxiga | $24,407 | $24,76322 claims |
| BayerKerendia | $324 | $23,94330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 285 nephrology providers in Maryland.
Other nephrology in Greenbelt
- Quan WangGreenbelt$16K
- Jonathan RudickGreenbelt$7K
- Ali IpakchiGreenbelt$7K
- Vishwam PandyaGreenbelt$6K
- Nirmala YadlaGreenbelt$3K
- Promod DuggalGreenbelt$3K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.